Efficacy and Safety of Orelabrutinib for Previously Treated Marginal Zone Lymphoma

Orelabrutinib monotherapy in MZL possesses favorable efficacy and safety in our study. Given the limited sample size, further clinical research with larger cohorts and extended follow-up is necessary.

Authors

Institutions

Publication Details

Journal
Journal of Hematology
Published
2025-12-01
DOI
https://doi.org/10.14740/jh2149
Primary Topic
Chronic Lymphocytic Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and Safety of Orelabrutinib for Previously Treated Marginal Zone Lymphoma

Xue Jiao, Shao Ling Wu, Yu Feng, Shan Wang et al.
Journal of Hematology
Chronic Lymphocytic Leukemia Research
article

Efficacy and Safety of Orelabrutinib for Previously Treated Marginal Zone Lymphoma

Xue Jiao, Shao Ling Wu, Yu Feng, Shan Wang, Shi Lv Chen
article en

Abstract

Orelabrutinib monotherapy in MZL possesses favorable efficacy and safety in our study. Given the limited sample size, further clinical research with larger cohorts and extended follow-up is necessary.

Journal of HematologyVol. 14(6)
Qingdao University (CN), Affiliated Hospital of Qingdao University (CN), Second Affiliated Hospital of Chengdu University of Traditional Chinese (CN), Chengdu University of Traditional Chinese Medicine (CN)
Openalex Percentile: Top 26%
Chronic Lymphocytic Leukemia Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.